Articles

The DESTINY-Breast06 phase 3 trial showed that trastuzumab deruxtecan significantly improved progression-free survival in HR-positive, HER2-low, HER2-ultralow metastatic breast cancer. Read More ›

The SOLTI VALENTINE phase 2 study explored HER3-DXd as a promising treatment for high-risk HR-positive/HER2-negative early breast cancer, showing the therapy’s ability to induce strong immune responses. Read More ›

Safety and efficacy data evaluating taletrectinib in patients diagnosed with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) were reported from the TRUST-I and TRUST-II phase 2 studies. Read More ›

The TROPION-Lung01 trial found a significant improvement in progression-free survival when comparing Dato-DXd to DTX in patients with advanced non-small cell lung cancer (NSCLC), particularly those with nonsquamous histology. Read More ›

The Explore ALK/ROS study investigated the management practices and clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) who tested positive for ROS1. Read More ›

A retrospective analysis was performed on deidentified records of patients with metastatic non-small cell lung cancer to assess adherence with the targeted therapy recommendations outlined in the ESMO and NCCN guidelines and to analyze the duration from genomic sequencing to the commencement of targeted treatment. Read More ›

This phase 2 study aimed to assess the efficacy and safety of a combination of pembrolizumab, plinabulin, and docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who have developed resistance to immunotherapy. Read More ›

The second interim analysis of overall survival from the BEAT-SC trial assessed bevacizumab for its effectiveness and safety in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) in Japan and China. Read More ›

This study evaluated real-world treatments and outcomes of limited disease small cell lung cancer (SCLC) using the Canadian SCLC Database (CASCADE). Read More ›

An ongoing, open-label, single-arm phase 2 study (IFCT-1904) evaluated patients with untreated BRAF V600E-mutant non-small cell lung cancer (NSCLC) who received encorafenib plus binimetinib. Read More ›